225. Congenital nephrogenic diabetes insipidus
12 clinical trials,   45 drugs   (DrugBank: 17 drugs),   30 drug target genes,   63 drug target pathways

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002204-38-DK
(EUCTR)
24/11/202007/05/2020Treatment of the genetic disease nephrogenic diabetes insipidus with the antifungal drug FluconazoleTreatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication Nephrogenic diabetes insipidus
MedDRA version: 21.0;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
INN or Proposed INN: Fluconazole
Other descriptive name: FLUCONAZOLE
Claus BistrupNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
10Phase 2Denmark